Characterization of a neutralizing monoclonal antibody against botulinum ADP-ribosyltransferase, C3 exoenzyme.
A monoclonal antibody, named C302, was prepared and characterized against botulinum ADP-ribosyltransferase C3 exoenzyme that inactivates RhoA GTP-binding protein, resulting in the neurite outgrowth of human neuroblastoma GOTO cells. C302 bound not to the smaller fragments derived from the protease-treated C3 exoenzyme but to the intact C3 exoenzyme. It seems that the C302 epitope may depend on the three-dimensional structure of C3 exoenzyme molecule. C302 depressed the enzymatic and biological actions of C3 exoenzyme. The dose-dependent depression pattern of C302 on the enzyme activity was similar to that to the biological one. C302 turned the neurite-bearing shape of the C3 exoenzyme-treated GOTO cells into the intact shape. By using of C302 mAb and C3 exoenzyme, the research concerning GTP-binding proteins would be improved.
Kamata
Yoichi
Y
Department of Veterinary Science, College of Agriculture, Osaka Prefecture University, Gakuen-cho, Sakai, Osaka, Japan.
Hoshi
Hidenobu
H
Choki
Hayato
H
Kozaki
Shunji
S
D036002:ADP Ribose Transferases / Q000037:antagonists & inhibitors* / Q000276:immunology* / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000494:pharmacology*; D001905:Botulinum Toxins / Q000037:antagonists & inhibitors* / Q000276:immunology* / Q000378:metabolism; D048429:Cell Size / Q000187:drug effects; D003014:Clostridium botulinum / Q000201:enzymology* / Q000276:immunology*; D006801:Humans; D016501:Neurites / Q000187:drug effects; D009447:Neuroblastoma / Q000378:metabolism / Q000473:pathology; D009500:Neutralization Tests; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D014407:Tumor Cells, Cultured; D020742:rhoA GTP-Binding Protein / Q000378:metabolism
D000911:Antibodies, Monoclonal; D036002:ADP Ribose Transferases; C063007:exoenzyme C3, Clostridium botulinum; D001905:Botulinum Toxins; D020742:rhoA GTP-Binding Protein